We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
+15.95%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$41.9M
AUM Growth
-$4.22M
Cap. Flow
-$8.19M
Cap. Flow %
-19.56%
Top 10 Hldgs %
48.42%
Holding
52
New
2
Increased
17
Reduced
26
Closed
5

Top Buys

Rank Stock Value
1
TSRO
TESARO, Inc.
TSRO
+$2.92M
2
CLVS
Clovis Oncology, Inc.
CLVS
+$2.69M
3
ACHN
Achillion Pharmaceuticals
ACHN
+$920K
4
ADMS
Adamas Pharmaceuticals
ADMS
+$693K
5
FBIO icon
Fortress Biotech
FBIO
+$499K

Top Sells

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$5.52M
2
BIB icon
ProShares Ultra NASDAQ Biotechnology
BIB
+$5.37M
3
IBB icon
iShares Biotechnology ETF
IBB
+$2.06M
4
BIIB icon
Biogen
BIIB
+$861K
5
AMGN icon
Amgen
AMGN
+$806K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RARE icon
26
Ultragenyx Pharmaceutical
RARE
$2.59B
$468K 1.12%
6,134
-177
-3% -$14.4K
TECH icon
27
Bio-Techne
TECH
$11.4B
$458K 1.09%
8,968
+1,340
+18% +$59.4K
ACAD icon
28
Acadia Pharmaceuticals
ACAD
$5.12B
$432K 1.03%
20,828
+5,500
+36% +$86.5K
NBIX icon
29
Neurocrine Biosciences
NBIX
$15.8B
$417K 1%
3,391
+326
+11% +$37K
AXSM icon
30
Axsome Therapeutics
AXSM
$10.8B
$415K 0.99%
120,150
-13,350
-10% -$39.6K
IQV icon
31
IQVIA
IQV
$43.2B
$409K 0.98%
3,156
+367
+13% +$44.1K
PGEN icon
32
Precigen
PGEN
$2.57B
$409K 0.98%
23,780
+6,200
+35% +$92.2K
CKPT
33
DELISTED
Checkpoint Therapeutics
CKPT
$404K 0.96%
11,276
– –
AKBA icon
34
Akebia Therapeutics
AKBA
$260M
$397K 0.95%
45,004
-5,000
-10% -$44.7K
AMGN icon
35
Amgen
AMGN
$236B
$382K 0.91%
1,841
-4,089
-69% -$806K
CRL icon
36
Charles River Laboratories
CRL
$14.2B
$380K 0.91%
2,826
+92
+3% +$11.4K
FBIO icon
37
Fortress Biotech
FBIO
$93.4M
$374K 0.89%
+15,602
New +$499K
BIIB icon
38
Biogen
BIIB
$32.7B
$365K 0.87%
1,032
-2,500
-71% -$861K
UTHR icon
39
United Therapeutics
UTHR
$22.6B
$359K 0.86%
2,805
+145
+5% +$17.9K
GRFS
40
Grifois
GRFS
$5.32B
$351K 0.84%
16,445
+4,003
+32% +$84.5K
GILD icon
41
Gilead Sciences
GILD
$185B
$350K 0.84%
4,533
+282
+7% +$21.3K
EXEL icon
42
Exelixis
EXEL
$13.7B
$292K 0.7%
16,475
+2,920
+22% +$56.9K
BLUE
43
DELISTED
bluebird bio
BLUE
$284K 0.68%
150
+24
+19% +$49.6K
PRTK
44
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$175K 0.42%
18,000
-2,000
-10% -$20.2K
CFRX
45
DELISTED
ContraFect Corporation
CFRX
$140K 0.33%
84
-10
-11% -$16.5K
SCTL
46
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$81K 0.19%
12,659
-1,407
-10% -$7.97K
SCYX icon
47
SCYNEXIS
SCYX
$54.9M
$36K 0.09%
375
-41
-10% -$4.84K
BIB icon
48
ProShares Ultra NASDAQ Biotechnology
BIB
$105M
– –
-93,805
Closed -$5.37M
IBB icon
49
iShares Biotechnology ETF
IBB
$10.8B
– –
-18,750
Closed -$2.06M
XBI icon
50
State Street SPDR S&P Biotech ETF
XBI
$11.7B
– –
-58,000
Closed -$5.52M
1
2
3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
FCM
Farmstead Capital Management Ridgewood, New Jersey $49M AUM 10.57% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return

Opus Point Partners Management's Q3 2018 Portfolio in Review

As of Q3 2018, Opus Point Partners Management held 52 positions worth $41.9M, down 9.2% from $46.1M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Opus Point Partners Management withdrew a net $8.19M in Q3 2018, closing 5 positions and reducing 26 holdings. Its most notable exit was State Street SPDR S&P Biotech ETF, an estimated $5.52M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 72% a quarter earlier.

Against the trend, Opus Point Partners Management opened a new position in Achillion Pharmaceuticals worth $1.14M.

  • Opus Point Partners Management's largest Q3 2018 buy was Achillion Pharmaceuticals: 308,569 shares worth $1.14M.
  • Opus Point Partners Management added most to TESARO, Inc. in Q3 2018, an estimated $2.92M increase.
  • Opus Point Partners Management's biggest Q3 2018 reduction was Biogen, cutting an estimated $861K.
  • Opus Point Partners Management fully exited State Street SPDR S&P Biotech ETF in Q3 2018, selling an estimated $5.52M.
  • Opus Point Partners Management's ten largest holdings make up 48% of its $41.9M portfolio in Q3 2018.
  • Opus Point Partners Management opened 2 new positions and closed 5 in Q3 2018.
  • Opus Point Partners Management's portfolio value fell 9.2% quarter-over-quarter to $41.9M.

Based on Opus Point Partners Management's 13F filing for Q3 2018, filed 14 Nov 2018.